International Prognostic Index for NHL | |
Five clinical risk factors: Age ≥60 years Serum lactate dehydrogenase levels elevated Performance status ≥2 (ECOG) or ≤70 (Karnofsky) Ann Arbor stage III or IV >1 site of extranodal involvement | |
| Pts are assigned a number for each risk factor they have. | |
| Pts are grouped differently based on the type of lymphoma. | |
| For diffuse large B-cell lymphoma: | |
| 0, 1 factor = low risk: | 35% of cases; 5-year survival, 73% |
| 2 factors = low-intermediate risk: | 27% of cases; 5-year survival, 51% |
| 3 factors = high-intermediate risk: | 22% of cases; 5-year survival, 43% |
| 4, 5 factors = high risk: | 16% of cases; 5-year survival, 26% |
| For diffuse large B-cell lymphoma treated with R-CHOP: | |
| 0 factor = very good: | 10% of cases; 5-year survival, 94% |
| 1, 2 factors = good: | 45% of cases; 5-year survival, 79% |
| 3, 4, 5 factors = poor: | 45% of cases; 5-year survival, 55% |
Abbreviations: ECOG, Eastern Cooperative Oncology Group; NHL, non-Hodgkin's lymphoma; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone.